NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 180)
Posted On: 09/26/2018 7:01:35 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Announces Joint Venture Agreement with Asterion Cannabis Inc.
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement to form a joint venture focused on the development of a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches and other jointly evaluated products aimed at treating various ailments such as chronic pain, inflammation, epilepsy and anxiety disorders. “This agreement between PreveCeutical and Asterion further supports our mission to improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release. “Our joint venture with Asterion comes at an important time, using Asterion’s high quality, low cost, genetically uniform strains of medicinal cannabis will allow PreveCeutical to supply the anticipated increasing demand for effective and personalised cannabis-based therapies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced its entry into an agreement to form a joint venture focused on the development of a range of medicinal cannabinoid products, including sublingual tablets, transdermal patches and other jointly evaluated products aimed at treating various ailments such as chronic pain, inflammation, epilepsy and anxiety disorders. “This agreement between PreveCeutical and Asterion further supports our mission to improve global health and healthcare by utilizing innovative science and cutting-edge technology to enhance natural products,” Stephen Van Deventer, chairman, CEO and president of PreveCeutical, stated in the news release. “Our joint venture with Asterion comes at an important time, using Asterion’s high quality, low cost, genetically uniform strains of medicinal cannabis will allow PreveCeutical to supply the anticipated increasing demand for effective and personalised cannabis-based therapies.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼